Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Fosnetupitant in Healthy Volunteers
NCT06840769Phase 1Terminated
- Sponsor
- Helsinn
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fosnetupitant in chemotherapy-induced nausea and vomiting (CINV) (5 arms), sponsored by Helsinn. Primary endpoints: Treatment-emergent Adverse Events, Number of Subjects With Treatment-emergent Adverse Events and 1 more. Started Jun 2023; status: terminated.
02
Drugs
fosnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06840769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840769.